Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 4793465, 7 pages
https://doi.org/10.1155/2017/4793465
Research Article

Response Detection of Castrate-Resistant Prostate Cancer to Clinically Utilised and Novel Treatments by Monitoring Phospholipid Metabolism

School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK

Correspondence should be addressed to Tim A. D. Smith; ku.ca.ndba@htims.t

Received 22 March 2017; Accepted 30 May 2017; Published 22 June 2017

Academic Editor: Christian Schwentner

Copyright © 2017 Tim A. D. Smith et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Heidenreich, P. J. Bastian, J. Bellmunt et al., “EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer,” European Urology, vol. 65, no. 2, pp. 467–479, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. R. J. Andersen, N. R. Mawji, J. Wang et al., “Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor,” Cancer Cell, vol. 17, no. 6, pp. 535–546, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. V. Kruse, S. Van Belle, and V. Cocquyt, “Imaging requirements for personalized medicine: The oncologists point of view,” Current Pharmaceutical Design, vol. 20, no. 14, pp. 2234–2249, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Ammari, R. Thiam, C. Cuenod et al., “Radiological evaluation of response to treatment: application to metastatic renal cancers receiving anti-angiogenic treatment,” Diagnostic and Interventional Imaging, vol. 95, no. 6, pp. 527–539, 2014. View at Publisher · View at Google Scholar
  6. Y. Ma, W. Xu, R. Bai et al., “Volume-based predictive biomarkers of sequential FDG-PET/CT for sunitinib in cancer of unknown primary: identification of the best benefited patients,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 44, no. 2, pp. 199–205, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. S. C. Van Es, C. M. Venema, A. W. J. M. Glaudemans et al., “Translation of new molecular imaging approaches to the clinical setting: bridging the gap to implementation,” Journal of Nuclear Medicine, vol. 57, pp. 96–104, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. I. N. Fleming, A. Andriu, and T. A. D. Smith, “Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: Role of the Akt-pathway, glucose transport and HIF-1α,” Breast Cancer Research and Treatment, vol. 144, no. 2, pp. 241–248, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Fodor, G. Berardi, C. Fiorino et al., “Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer,” BJU International, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Al-Saeedi, A. E. Welch, and T. A. D. Smith, “Choline incorporation into MCF7 tumour cells: Correlation with proliferation,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 32, no. 6, pp. 660–667, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. R. F. Kletzien and J. F. Perdue, “Sugar transport in chick embryo fibroblasts,” The Journal of Biological Chemistry, pp. 249–3366, 1974. View at Google Scholar
  12. T. A. D. Smith and S. M. Phyu, “Metformin decouples phospholipid metabolism in breast cancer cells,” PLoS ONE, vol. 11, no. 3, Article ID e0151179, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Smith and S. Phyu, “Determination of Rate of [3H-methyl]-choline Incorporation into Cellular Lipids and Non-lipid Metabolites,” BIO-PROTOCOL, vol. 6, no. 22, 2016. View at Publisher · View at Google Scholar
  14. A. L. Zhang, P. J. Russell, T. Knittel, and C. Milross, “Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway,” Prostate, vol. 67, no. 15, pp. 1630–1640, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. Y.-L. Chung, H. Troy, R. Kristeleit et al., “Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts,” Neoplasia, vol. 10, no. 4, pp. 303–313, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. S. M. Phyu, C.-C. Tseng, I. N. Fleming, and T. A. D. Smith, “Probing the PI3K/Akt/mTor pathway using 31P-NMR spectroscopy: Routes to glycogen synthase kinase 3,” Scientific Reports, vol. 6, Article ID 36544, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. J. P. Wijnen, W. J. M. Van Der Kemp, M. P. Luttje, M. A. Korteweg, P. R. Luijten, and D. W. J. Klomp, “Quantitative 31P magnetic resonance spectroscopy of the human breast at 7 T,” Magnetic Resonance in Medicine, vol. 68, no. 2, pp. 339–348, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. N. M. S. Al-Saffar, L. E. Jackson, F. I. Raynaud et al., “The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase α leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy,” Cancer Research, vol. 70, no. 13, pp. 5507–5517, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Esmaeili, S. A. Moestue, B. C. Hamans et al., “In vivo 31P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts,” Journal of Magnetic Resonance Imaging, vol. 41, no. 3, pp. 601–609, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. B. F. Jordan, K. Black, I. F. Robey, M. Runquist, G. Powis, and R. J. Gillies, “Metabolite changes in HT-29 xenograft tumors following HIF-1α inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo,” NMR in Biomedicine, vol. 18, no. 7, pp. 430–439, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Popovics, D. E. Frigo, A. V. Schally, and F. G. Rick, “Targeting the 5′-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer,” Expert Opinion on Therapeutic Targets, vol. 19, no. 5, pp. 617–632, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. J. B. Tennakoon, Y. Shi, J. J. Han et al., “Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch,” Oncogene, vol. 33, no. 45, pp. 5251–5261, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Li, J. Satriano, J. L. Thomas et al., “Interactions between HIF-1α and AMPK in the regulation of cellular hypoxia adaptation in chronic kidney disease,” American Journal of Physiology - Renal Physiology, vol. 309, no. 5, pp. F414–F428, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. M. W. Lagemaat, M. C. Maas, E. K. Vos et al., “31P MR spectroscopic imaging of the human prostate at 7 T: T1 relaxation times, Nuclear Overhauser Effect, and spectral characterization,” Magnetic Resonance in Medicine, vol. 73, no. 3, pp. 909–920, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. S. A. Moestue, G. F. Giskeodegard, T. F. Cao, I. S. Gribbestad, M. D. Cao, and T. F. Bathen, “Glycerophosphocholine (GPC) is a poorly understood biomarker in breast cancer,” Proceedings of the National Academy of Sciences, pp. 109–E2506, 2012. View at Google Scholar
  26. J. P. Wijnen, L. Jiang, T. R. Greenwood et al., “Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by 31P MRS,” NMR in Biomedicine, vol. 27, no. 6, pp. 692–699, 2014. View at Publisher · View at Google Scholar · View at Scopus